To evaluate the association between intravitreal anti-vascular endothelial growth factor (VEGF) therapy and visual acuity (VA)/driving vision maintenance over 4 years in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Retrospective, observational, real-world cohort study using data from the Vestrum Health database.
Initial diagnosis (January 1, 2014-June 30, 2019) of nAMD or DME and ≥1 year of treatment/follow-up history. The VA analysis required 4 years of treatment/follow-up history. For the driving vision maintenance analysis, patients required Snellen VA of 20/40 or better at baseline and for ≥6 months during year 1 after index intravitreal anti-VEGF treatment in the better-seeing eye.
A loss-of-driving event was the first clinic visit with VA worse than 20/40 sustained for ≥6 consecutive months. Kaplan-Meier analyses estimated the probability of maintaining driving vision over 4 years stratified by year-1 injection number. Cox proportional hazard models examined associations between baseline clinical characteristics and year 1 injection frequency and the risk of losing driving vision.
Mean change in VA over time and by baseline VA, driving vision maintenance probability over time and stratified by anti-VEGF injection frequency, and baseline factors predictive of driving vision maintenance.
In year 1, the nAMD and DME cohorts gained 8.5 and 9.5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, respectively. Between years 1-4, patients with nAMD and DME lost 6.6 and 2.7 ETDRS letters, respectively. The probability of maintaining driving vision over 4 years was 56% (nAMD) and 72% (DME); among patients who received 1-5, 6-7, and ≥8 anti-VEGF injections in year 1, corresponding probabilities were 50%, 56%, and 65% (nAMD; P<0.001) and 63%, 72%, and 77% (DME; P<0.001). Baseline factors associated with driving vision loss included older age, worse index VA, geographic atrophy (nAMD), and worsening baseline diabetic retinopathy (DME).
Older age and worse index VA were risk factors for driving vision loss, whereas a greater year-1 injection number was associated with driving vision maintenance through year 4, supporting early initiation and frequent anti-VEGF injections for maintaining driving vision in nAMD or DME.

Copyright © 2023. Published by Elsevier Inc.